Back to Journals » Infection and Drug Resistance » Volume 13

Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series

Authors Mahmoud E, Al Mansour S, Bosaeed M, Alharbi A, Alsaedy A, Aljohani S, Alalwan B, Alothman A

Received 18 March 2020

Accepted for publication 16 July 2020

Published 3 August 2020 Volume 2020:13 Pages 2667—2672


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Suresh Antony

Ebrahim Mahmoud,1 Sarah Al Mansour,1 Mohammad Bosaeed,1– 3 Ahmad Alharbi,1 Abdulrahman Alsaedy,1,2 Sameera Aljohani,2,4 Bassam Alalwan,4 Adel Alothman1,2,

1Division of Infectious Diseases, Department of Medicine, King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia; 2College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 3King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia; 4Department of Pathology & Laboratory Medicine, King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia

†Doctor Adel Al Othman passed away on June 8, 2020

Correspondence: Ebrahim Mahmoud
Division of Infectious Diseases, Department of Medicine, King Abdulaziz Medical City - Riyadh, P.O. Box 22490, Riyadh 11426, Saudi Arabia
Tel +966 500081418

Abstract: While methicillin-resistant Staphylococcus aureus (MRSA) bacteremia has poor outcomes, we describe our experience with Ceftobiprole mainly as a combination therapy for the treatment of MRSA bacteremia. All the cases of MRSA bacteremia in our center at the King Abdulaziz Medical City (KAMC), Riyadh, that had undergone Ceftobiprole treatment were included. We had six cases of MRSA bacteremia between 2018 and 2019, secondary to different infectious syndromes including endocarditis. There was a severe infection that required intensive care unit (ICU) admission in four cases. Ceftobiprole is used in combination with vancomycin in four cases. On day 14, all cases had a favorable outcome with microbiological and clinical improvement. However, three patients died after months of suffering from bacteremia from unrelated causes for the infection. The clinical outcome in our series of treatment of MRSA bacteremia using Ceftobiprole was favorable. Further studies for the evaluation of the use of Ceftobiprole in MRSA bacteremia should be encouraged.

Keywords: methicillin-resistant Staphylococcus aureus, bacteremia, Ceftobiprole, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]